Tong Ren Tang Technologies Past Earnings Performance
Past criteria checks 2/6
Tong Ren Tang Technologies has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 9% per year. Tong Ren Tang Technologies's return on equity is 10.3%, and it has net margins of 8.7%.
Key information
2.5%
Earnings growth rate
2.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 9.0% |
| Return on equity | 10.3% |
| Net Margin | 8.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tong Ren Tang Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,773 | 590 | 1,732 | 0 |
| 30 Sep 23 | 6,849 | 611 | 1,652 | 0 |
| 30 Jun 23 | 6,924 | 633 | 1,572 | 0 |
| 31 Mar 23 | 6,458 | 608 | 1,475 | 0 |
| 31 Dec 22 | 5,992 | 583 | 1,378 | 0 |
| 30 Sep 22 | 5,820 | 546 | 1,331 | 0 |
| 30 Jun 22 | 5,649 | 510 | 1,284 | 0 |
| 31 Mar 22 | 5,525 | 509 | 1,248 | 0 |
| 31 Dec 21 | 5,400 | 507 | 1,212 | 0 |
| 30 Sep 21 | 5,267 | 509 | 1,226 | 0 |
| 30 Jun 21 | 5,133 | 511 | 1,240 | 0 |
| 31 Mar 21 | 4,870 | 489 | 1,182 | 0 |
| 31 Dec 20 | 4,607 | 468 | 1,125 | 0 |
| 30 Sep 20 | 4,425 | 387 | 1,099 | 0 |
| 30 Jun 20 | 4,242 | 307 | 1,073 | 0 |
| 31 Mar 20 | 4,359 | 362 | 1,094 | 0 |
| 31 Dec 19 | 4,476 | 418 | 1,116 | 0 |
| 30 Sep 19 | 4,604 | 523 | 1,099 | 0 |
| 30 Jun 19 | 4,731 | 628 | 1,082 | 0 |
| 31 Mar 19 | 4,895 | 653 | 1,157 | 0 |
| 31 Dec 18 | 5,060 | 678 | 1,231 | 0 |
| 30 Sep 18 | 5,054 | 681 | 1,295 | 0 |
| 30 Jun 18 | 5,047 | 683 | 1,359 | 0 |
| 31 Mar 18 | 5,036 | 675 | 1,359 | 0 |
| 31 Dec 17 | 5,025 | 667 | 1,359 | 0 |
| 30 Sep 17 | 4,882 | 624 | 1,367 | 0 |
| 30 Jun 17 | 4,739 | 582 | 1,375 | 0 |
| 31 Mar 17 | 4,702 | 589 | 1,367 | 0 |
| 31 Dec 16 | 4,665 | 596 | 1,359 | 0 |
| 30 Sep 16 | 4,546 | 603 | 1,297 | 0 |
| 30 Jun 16 | 4,426 | 610 | 1,235 | 0 |
| 31 Mar 16 | 4,247 | 575 | 1,183 | 0 |
| 31 Dec 15 | 4,067 | 541 | 1,131 | 0 |
| 30 Sep 15 | 3,915 | 529 | 1,081 | 0 |
| 30 Jun 15 | 3,764 | 517 | 1,032 | 0 |
| 31 Mar 15 | 3,552 | 490 | 968 | 0 |
| 31 Dec 14 | 3,341 | 462 | 904 | 0 |
| 30 Sep 14 | 3,246 | 446 | 879 | 0 |
| 30 Jun 14 | 3,151 | 430 | 855 | 0 |
| 31 Mar 14 | 3,031 | 410 | 841 | 0 |
| 31 Dec 13 | 2,911 | 390 | 826 | 0 |
| 30 Sep 13 | 2,833 | 387 | 815 | 0 |
| 30 Jun 13 | 2,755 | 384 | 803 | 0 |
Quality Earnings: TNG has high quality earnings.
Growing Profit Margin: TNG's current net profit margins (8.7%) are lower than last year (9.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNG's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: TNG's earnings growth over the past year (1.3%) is below its 5-year average (2.5% per year).
Earnings vs Industry: TNG earnings growth over the past year (1.3%) did not outperform the Pharmaceuticals industry 2.6%.
Return on Equity
High ROE: TNG's Return on Equity (10.3%) is considered low.